Revenue
Margin
Demand
Guidance
Tone
Event Participants
Executives
3
Abhinandan Singh, Angan Guha, Chandrasekar Thyagarajan
Analysts
6
Amit Chandra, Dipesh Mehta, Priyank Chheda, Rushabh Jain, Sandeep Shah, Vibhor Singhal
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue | $145.2 million; ₹1,379.4 crore | +0.3% QoQ in constant currency, flattish QoQ in USD; +2.3% QoQ and +7.4% YoY in INR. Growth driven by BFSI and LSS, offset by softness in Manufacturing and E&U. |
| Deal TCV signings | $168.7 million | +20% YoY vs $140 million in Q1 FY26; includes several AI-led engagements. Q1 is traditionally a weak signing quarter; Q3/Q4 FY26 were $200 million+. |
| EBITDA | ₹222 crores | +40.3% YoY; excludes one-off tailwinds that benefited Q4 FY26 by ~170 bps. |
| EBITDA margin | 16.1% | Normalized, closer to sustainable 15%+ range; Q2 FY27 to absorb wage-hike impact with productivity offsets. |
| Quarterly collections | $163.1 million | Exceeded quarterly revenue, driving cash build and DSO improvement. |
| DSO | 55 days | Improved QoQ; management termed it among the best in the industry. |
| Cash and cash equivalents | ₹2,878.6 crore | +9% QoQ, +26% YoY; robust balance sheet supporting continued investment. |
| Operating cash flow / EBITDA | 108% | Healthy cash conversion in Q1. |
| Basic EPS (non-annualized) | ₹5.72 | Reflects normalized ETR; tax for the quarter was $16.9 million / ₹161 crore. |
| Effective tax rate (ETR) | 29.4% | Sequentially higher as Q4 FY26 benefited from tax concessions in global operations; FY27 guided at 29-30%. |
Geographic & Segment Commentary
- BFSI: Strong sequential growth; won a strategic AI partnership with a leading US financial services player (design, pilot, scale AI use cases) and renewed/expanded the same client's run-support into an AI-first operating model. Management expects BFSI to remain a growth driver through the year.
- Life Sciences (LSS): Grew sequentially; secured a strategic GenAI engagement with a leading global pharma/medtech company for pharmacovigilance operations. Management expects LSS to bounce back after earlier softness.
- Manufacturing: Continued softness in the quarter; largest vertical but cyclical. Management is investing heavily to turn it around, with recovery expected in a couple of quarters.
- Energy & Utilities (E&U): Softness expected for one more quarter, with turnaround guided from Q3 FY27 onwards; together with Manufacturing, contributes ~50% of revenue.
- Geographies: Marquee AI-led wins in the US and Europe; no geographic revenue split disclosed in the call.
Company-Specific & Strategic Commentary
- AI-Led Deal Momentum: Selected as strategic AI partner for a leading US financial services firm; won a multi-year AI-led transformation with a European banking group (core modernization, cloud migration, legacy replacement); secured GenAI pharmacovigilance deployment for a global pharma/medtech major.
- AI Platforms & Engineering: Cogito (enterprise agentic AI orchestration with governance, no model/cloud lock-in) demonstrated to 15+ clients; launched Lynx (AI-powered test engineering) and Sigma (agentic AIOps/AMS); over a quarter of code now generated via agentic AI tools; top 10 service offerings re-engineered AI-first with human-in-the-loop controls.
- Sales & Leadership Expansion: New leaders onboarded across data/AI, ERP, global partnerships, and LSS vertical; significant sales team additions expected over the next few months; sales/support headcount rebalanced toward revenue-generating line roles.
- Capital Allocation: Board "seized on" capital allocation; shareholder rewards and capability-based inorganic M&A under consideration. Management ruled out revenue-aggregation acquisitions and is prioritizing organic growth before deal-making.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue growth | No formal FY27 guidance; momentum expected to sustain | Strong pipeline, +20% YoY TCV, and protected renewals cited; execution over remaining two months of Q2 critical. |
| Deal signings | H1 FY27 to be "much better" than H1 FY26 | Driven by healthier pipeline, new sales muscle, and AI-infused deal flow; full-year signings expected above FY26 as renewals cluster in Q3/Q4. |
| EBITDA margin | At or above 15% for FY27 | Q2 to absorb ~half of the 170-200 bps wage-hike impact, recovered through productivity gains through the year. |
| Effective tax rate | 29-30% for FY27 | Normalization after FY26 US federal tax provision and Q4 FY26 one-off tax concessions. |
| Vertical recovery | E&U turnaround from Q3 FY27; Manufacturing in a couple of quarters | BFSI expected strong for the year; LSS expected to bounce back; order book is the lead indicator for revenue. |
Risks & Constraints
| Risk | Context |
|---|---|
| AI-driven pricing deflation | Clients are baking promised productivity gains into new and renewed deals, creating a gap between TCV growth and revenue conversion. Management expects convergence over the next 3-4 quarters; industry-wide phenomenon. |
| Vertical concentration | Manufacturing and E&U together contribute ~50% of revenue and are both soft. Recovery depends on order book conversion and turnaround investments; E&U not expected to improve before Q3 FY27. |
| Intense competition in AI deals | AI-led deals are "fiercely contested," increasingly by larger players. Birlasoft is winning its fair share, but competition could pressure margins or win rates. |
| Wage inflation | 170-200 bps EBITDA impact from the July wage hike; roughly half hits Q2 FY27 P&L, partially offset by productivity gains. |
| Execution risk on growth | Management refrained from formal guidance citing a volatile demand environment; momentum hinges on sales additions and deal signings converting to revenue. |
| Client rationalization | Active clients down to ~213 after tail rationalization; growth concentrated in top 36 accounts (80% of revenue), with new-account addition yet to show up in reported metrics. |
Q&A Highlights
Revenue Momentum and Order Book
- Question: How confident are you on sustaining the QoQ constant-currency growth, and what are the vertical-wise demand trends? (Dipesh Mehta, Emkay Global)
- Answer: Management is confident momentum will sustain, though two months of the quarter remain; BFSI and LSS should remain strong, while manufacturing weakness continues and is being addressed through investment. (Angan Guha)
- Question: What does "momentum" mean, given Q1 TCV was below the $200 million+ of Q3/Q4 FY26 and sales headcount remains below pre-COVID levels? (Priyank Chheda, Vallum Capital)
- Answer: Momentum = deal signings and healthy pipeline; Q1 is traditionally a weak signing quarter; TCV was up 20% YoY with net new up ~$15 million; H1 FY27 signings will be "much better" than H1 FY26; material sales muscle will be added over the next quarter. (Angan Guha)
- Question: If momentum sustains, can we assume no negative growth in the remaining three quarters? (Sandeep Shah, Equirus Securities)
- Answer: Management declined to give guidance but said the order book is the lead indicator; Q3/Q4 FY26 and Q1 FY27 order books were strong, and revenue will follow signings. (Angan Guha)
EBITDA Margin and Wage Hike
- Question: Earlier the normalized margin trajectory was ~15%; is 16% the new normalized level? (Dipesh Mehta, Emkay Global)
- Answer: Management maintains a 15%+ EBITDA margin target; 16.1% was delivered without one-offs. The July wage hike (170-200 bps full impact) will dilute Q2 by roughly half that amount, but productivity improvements should recover it, keeping margins at or above 15%. (Chandrasekar Thyagarajan)
- Question: Is the entire wage hike effective in Q2 alone? (Vibhor Singhal, Nuvama Equities)
- Answer: Yes, effective July 1, not phased. (Chandrasekar Thyagarajan)
Deal Wins, Tenure, and Competitive Landscape
- Question: Any change in deal tenure or nature — are there short-term projects that need backfilling? (Vibhor Singhal, Nuvama Equities)
- Answer: No material change; deal tenures are 18-24 months, and many Q1 deals now carry an AI component; Q1 TCV of $168.7 million was up 20% YoY. (Angan Guha)
- Question: How intense is competition in AI-led deals, especially from larger players? (Vibhor Singhal, Nuvama Equities)
- Answer: All such deals are fiercely contested; Birlasoft is winning its fair share. (Angan Guha)
- Question: Why the gap between TCV growth and revenue growth, and when will they converge? (Amit Chandra, HDFC Securities)
- Answer: Productivity gains and pricing pressure from AI-led delivery compress revenue conversion; convergence should occur over the next 3-4 quarters as the industry stabilizes; renewals are being protected. (Angan Guha)
Capital Allocation and Cash Deployment
- Question: With cash balances rising, how do you plan to deploy cash? (Dipesh Mehta, Emkay Global)
- Answer: The board will continue rewarding shareholders while pursuing well-considered organic/inorganic capability building; no revenue-aggregation acquisitions; focus on sustainable, profitable, predictable growth. (Chandrasekar Thyagarajan)
- Question: Cash is ~one-third of market cap and hurting return ratios; will you define a capital allocation policy with timelines, including buyback? (Priyank Chheda, Vallum Capital)
- Answer: This feedback will be conveyed to the board. (Angan Guha)
- Question: Any acquisition gaps in portfolio/geography being evaluated? (Amit Chandra, HDFC Securities)
- Answer: Only capability-building AI assets will be considered; priority is delivering 3-4 quarters of organic growth first so the company can consume an acquisition without management distraction. (Angan Guha)
Sales Build-Out and Client Rationalization
- Question: Sales team additions were guided at 30-40% by Q2, but headcount remains below pre-COVID and client counts keep rationalizing. (Priyank Chheda, Vallum Capital)
- Answer: Headline sales-and-support numbers mask a shift toward line/sales and domain roles as support is rationalized; active accounts stand at ~213; rationalization is complete; top 36 accounts contribute ~80% of revenue, and new sales hires will expand real estate over the next 1-2 quarters. (Angan Guha; Chandrasekar Thyagarajan)
Balance Sheet Deep-Dive
- Question: Why such a sharp jump in unbilled revenue and decline in fixed-price project revenue in the annual report? (Rushabh Jain, Axis Capital)
- Answer: Billing was delayed on two clients due to documentation issues as of March FY26; this has been regularized, reflected in higher Q1 collections and improved DSO of 55 days; further balance-sheet improvement is a continuing effort. (Chandrasekar Thyagarajan)
Tax Rate and Vertical Outlook
- Question: What is the FY27 ETR assumption? (Sandeep Shah, Equirus Securities)
- Answer: 29-30% for FY27. (Chandrasekar Thyagarajan)
- Question: Manufacturing + E&U is ~50% of revenue; if recovery takes time, is a stronger H2 vs H1 the right way to look at FY27? (Sandeep Shah, Equirus Securities)
- Answer: Yes; BFSI should do well for the year, LSS should bounce back, while Manufacturing and E&U need a couple of quarters; order book will lead revenue. (Angan Guha)
Key Takeaway
Birlasoft started FY27 with a steady but modest quarter: consolidated revenue of $145.2 million (₹1,379.4 crore; +0.3% QoQ CC, +7.4% YoY INR), as BFSI and LSS offset continued softness in Manufacturing and E&U. EBITDA normalized to 16.1% (₹222 crore, +40.3% YoY) without the ~170 bps Q4 one-off, while ₹2,878.6 crore of cash (+9% QoQ), 55-day DSO, and 108% OCF/EBITDA underscored balance-sheet strength. TCV signings of $168.7 million (+20% YoY) were anchored by AI-led deals in US financial services, European banking, and pharma/medtech pharmacovigilance, supporting management's confidence that momentum will sustain and H1 FY27 signings will exceed H1 FY26. Strategy centers on scaling Cogito, Lynx, and Sigma AI platforms, materially expanding sales, and holding EBITDA margins at or above 15% despite a 170-200 bps July wage hike. Watch items: manufacturing/E&U recovery by Q3, AI-driven pricing deflation, and capital-allocation decisions on the growing cash pile.